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The widespread resistance of malaria parasites to all
affordable drugs has made the identification of new
targets urgent. Dipeptidyl aminopeptidases (DPAPs)
represent potentially valuable new targets that are
involved in hemoglobin degradation (DPAP1) and
parasite egress (DPAP3). Here we use activity-based
probes to demonstrate that specific inhibition of
DPAP1 by a small molecule results in the formation
of an immature trophozoite that leads to parasite
death. Using computational methods, we designed
stable, nonpeptidic covalent inhibitors that kill
Plasmodium falciparum at low nanomolar concen-
trations. These compounds show signs of slowing
parasite growth in a murine model of malaria, which
suggests that DPAP1 might be a viable antimalarial
target. Interestingly, we found that resynthesis and
activation of DPAP1 after inhibition is rapid, suggest-
ing that effective drugs would need to sustain DPAP1
inhibition for a period of 2–3 hr.
INTRODUCTION
Malaria remains one of themost devastating infectious diseases,
with more than a quarter billion clinical cases and close to a
million deaths per year (Aregawi et al., 2008). Yet, the most
dramatic aspect of the disease is the widespread resistance
of Plasmodium species to all affordable frontline drugs. Multi-
drug-resistant strains are commonly identified in field isolates
(Chaijaroenkul et al., 2005; Wilairatana et al., 2002; Wongsricha-
nalai et al., 2002), and the first signs of resistance to artemisinin-
based combination therapy, the current gold standard for treat-
ment, are starting to appear in Southeast Asia (Dondorp et al.,
2009; Noedl et al., 2009; Rogers et al., 2009). It is therefore
urgent to develop new strategies to combat malaria and espe-
cially to identify new drug targets.
The success of protease inhibitors for the treatment of HIV
and hypertension has put this class of enzymes at the forefront
of drug development. In a wide range of pathologies such
as cancer, diabetes, or hepatitis C, protease inhibitors have808 Chemistry & Biology 17, 808–819, August 27, 2010 ª2010 Elsevireached an advanced stage of clinical development (Fear
et al., 2007). The central role of proteases in parasitic diseases
(McKerrow et al., 2006, 2008), and the wealth of knowledge
about protease inhibitors have made these enzymes one of the
target families for neglected diseases. For example, inhibitors
of cruzain, a Trypanosoma cruzi cysteine protease, are currently
in the advanced stages of preclinical trials for the treatment of
Chagas disease (McKerrow et al., 2009).
Although there are multiple species of parasites that cause
malaria, Plasmodium falciparum is the most virulent and
accounts for more than 90% of all malarial related deaths. Prote-
ases are essential throughout the erythrocytic cycle of P. falcipa-
rum and are involved in a variety of biological processes such as
hemoglobin degradation (Goldberg, 2005), protein trafficking
(Binder and Kim, 2004), rupture (Blackman, 2008; Roiko and
Carruthers, 2009), and red blood cell invasion (Dowse et al.,
2008). Furthermore, inhibition of cysteine proteases results in
the disruption of parasite growth, egress, and invasion.
However, the study of cysteine proteases in P. falciparum has
mainly focused on the falcipains (FPs). FP2, 20, and 3 are active
in the food vacuole (FV) and are involved in hemoglobin degrada-
tion (Rosenthal, 2004), the main source of amino acids during
parasite growth. FP1 is expressed at the later stages of the
erythrocytic cycle and is likely involved in host cell invasion
(Greenbaum et al., 2002).
Dipeptidyl aminopeptidases (DPAPs) were recently identified
as key regulators of the erythrocytic cycle of P. falciparum.
DPAP1 (PF11_0174) is localized to the FV and is believed to be
involved in the final stages of the hemoglobin degradation
pathway (Klemba et al., 2004). This protease degrades oligopep-
tideproductsof upstreamproteases intodipeptides that can then
be converted into single amino acids by aminopeptidases (Dalal
and Klemba, 2007; Klemba, 2009; Ragheb et al., 2009). Although
a GFP-tagged DPAP1 had been successfully cloned into 3D7 P.
falciparum, DPAP1 has been refractory to genetic deletion sug-
gesting that it is an essential protease (Klemba et al., 2004).
DPAP3 (PFD0230c) is also expressed in an active form during
the erythrocytic cycle of P. falciparum. We recently identified this
protease as a key regulator of parasite egress (Arastu-Kapur
et al., 2008). Because DPAPs are involved at distinct stages of
the parasite life cycle, they have the potential to be valuable
drug targets. Since each DPAP is likely to be essential, a drug
that is able to target all of these proteases may be less likely to
induce resistance because it disrupts multiple biologicaler Ltd All rights reserved
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DPAP1 Inhibition in P. falciparumprocesses. Additionally, DPAP2 (PFL2290w), the last member of
the DPAP family, is mainly expressed in gametocytes (Young
et al., 2005), where its function remains largely unknown.
DPAPs are also potentially good drug targets because the
closest human homolog is cathepsin C (hCat C), a protease
that is not essential in mammals. Although hCatC directly acti-
vates a family of serine proteases involved in inflammation and
the immune response (Adkison et al., 2002; Pham and Ley,
1999), a recent study in rats showed that more than 90%of Cat C
activity needs to be inhibited in order to see any significant
decrease in the levels of serine protease activities (Methot
et al., 2007, 2008). Moreover, continuous inhibition of Cat C
for several weeks is not toxic to rats (Methot et al., 2008). Finally,
Cat C knockout mice are healthy and reproduce normally (Pham
and Ley, 1999). DPAPs differ from other endopeptidases in that
they recognize the N-terminal free amine of substrate proteins
and cleave N-terminal dipeptides. Structurally, in addition to
the heavy and light chains of a papain-fold catalytic domain,
DPAPs also possess an exclusion domain positioned such
that it occludes access to the active site beyond the P2 position,
thus forming a heterotrimer (Olsen et al., 2001; Turk et al., 2001).
The exclusion domain N-terminal aspartate directly interacts
with the N-terminal amino group of substrates. Therefore, the
active sites of DPAPs are relatively small compared to that of
other endopeptidases, and most of their substrate specificity
is dictated by the N-terminal residue (P2). This smaller active
site is more amenable to binding of low molecular weight drug
leads and should be more suitable for computational docking
and in silico design of inhibitors.
Given the lack of readily available techniques to conditionally
disrupt gene expression in P. falciparum, it will be necessary to
use highly specific compounds to demonstrate that DPAPs are
viable drug targets. In this study, we demonstrate that a highly
selective inhibitor of DPAP1 causes a block in progression of
the blood stage life cycle and subsequently kills parasites. While
this selective lead compound was a valuable tool for in vitro
studies, its overall lack of stability prevented its use for in vivo
studies. Therefore, we used computational methods to design
potent nonpeptidic inhibitors of DPAP1 that could be used in
mouse models of malaria. Our most potent lead compounds
kill P. falciparum at single-digit nanomolar concentrations in
culture, are stable in mouse serum, and, although toxic
in vivo, cause a decrease in parasite load in a mouse model of
malaria. Furthermore, our studies demonstrate that effective
parasite killing by DPAP1 inhibitors requires sustained inhibition
of its protease as the result of rapid recovery of activity after
inhibition.
RESULTS
Selective Inhibition of DPAP1 Kills P. falciparum
in Culture
In order to validate DPAP1 as a drug target, we needed to identify
selective inhibitors. Specifically, we needed to avoid inhibition of
the FPs or DPAP3 since these are also essential papain-fold
cysteine proteases. Ala-4(I)Phe-DMK (Figure 1A) was initially
developed by Merck as an irreversible inhibitor of hCat C
(Guay et al., 2009; Methot et al., 2007). The diazomethyl ketone
(DMK) reactive group, which selectively targets cysteine prote-Chemistry & Biology 17, 80ases (Powers et al., 2002), covalently modifies the catalytic
active site cysteine of hCat C. In order to assess the specificity
of Ala-4(I)Phe-DMK for DPAP1, DPAP3, and the FPs, we per-
formed competition assays using several activity-based probes
(ABPs). In these assays, the inhibitor is added to total parasite
extracts and inhibition is determined by labeling of residual
active proteases with the ABP (Arastu-Kapur et al., 2008). We
found that Ala-4(I)Phe-DMK efficiently blocked labeling of
DPAP1 but not FPs or DPAP3 (Figure 1B), indicating that it is
DPAP1 selective.
To confirm that Ala-4(I)Phe-DMK acts as a covalent, irrevers-
ible inhibitor, we measured the dose response for DPAP1 inhibi-
tion at various time points using the (Pro-Arg)2-Rho fluorogenic
substrate. We have previously demonstrated that this substrate
is only processed by DPAP1 in parasite lysates (Deu et al., 2010).
As expected for an irreversible inhibitor, the IC50 values
decreased in a time dependent manner (Figure 1C). Further-
more, these data confirm that Ala-4(I)Phe-DMK is a potent inhib-
itor of DPAP1 with a second order rate constant of inhibition (ki)
of 35,000 ± 3000 M1s1.
To test whether DPAP1 inhibition results in parasite death, we
treated ring stage parasites for75 hr with Ala-4(I)Phe-DMK and
measured the fraction of infected RBCs by FACS (Figure 1D).
The half maximal parasite growth dose (EC50Pot) for Ala-4(I)
Phe-DMK (2.8 nM) was similar to the half maximal inhibition
dose for a 2 hr treatment (IC50DPAP1, 2 hr) of parasite lysates
(2.0 nM; Figure 1C), which suggests that specific inhibition of
DPAP1 directly correlates with parasite death. Moreover, the
EC50Pot measured after 1 hr treatment at trophozoite stage
(16 nM) is similar to the IC50DPAP1, 1 hr measured in lysates
(6.4 nM) (Figure 2).
Trophozoite Stage Parasites Are Most Sensitive
to DPAP1 Inhibition
Since Ala-4(I)Phe-DMK is a DPAP1-specific inhibitor, it could be
used to determine whether a specific phenotype is associated
with DPAP1 inhibition in live parasites.We treated a synchronous
culture at either ring or schizont stage for 24 hr with Ala-4(I)Phe-
DMK and monitored the parasites by thin blood smears
(Figure 1E). Control treated ring stage parasites developed into
mature schizonts that occupy most of the RBC volume. With
increasing concentrations of the inhibitor, we observed a
decrease in the size of the trophozoites. This same phenotype
was observed for other classes of DPAP1-selective inhibitors
such as SAK2 (Arastu-Kapur et al., 2008) suggesting that this
effect is likely due to specific target inhibition rather than off-
target effects (see Figure S1 available online). These observa-
tions suggest that DPAP1 is involved in trophozoite growth,
which agrees with its gene expression profile (Bozdech et al.,
2003; Le Roch et al., 2003; Llinas et al., 2006) and its proposed
role in hemoglobin degradation (Klemba et al., 2004). The lack
of a FV defect when ring parasites were treated with Ala-4(I)
Phe-DMK confirms that this inhibitor does not target FP2, 20, or
3. In addition, we treated schizonts with Ala-4(I)Phe-DMK for
24 hr and found that at 200 nM it causes a significant decrease
in the number of rings and an increase in schizonts (Figure 1E).
This suggests that DPAP1 inhibition might also delay egress.
At higher concentrations (R1 mM), it also induces schizont arrest
and a FV defect, which might be a result from cross-reactivity8–819, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 809
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Figure 1. Selective Inhibition of DPAP1 Results in Parasite Death
(A) Structure of Ala-4(I)Phe-DMK.
(B) DPAP and Falcipain (FP) inhibition by Ala-4(I)Phe-DMK. Trophozoites ormerozoites lysates were incubated for 30minwith 10 mMof Ala-4(I)Phe-DMK followed
by 1 hr labeling with FY01 or 125I-DCG04. Labeling was analyzed by fluorescent scan of SDS-PAGE gels or autoradiography, respectively. Loss of labeling
indicates inhibition of the indicated protease.
(C) Ala-4(I)Phe-DMK acts as an irreversible inhibitor. Trophozoite lysates were incubated with inhibitor for 0.1–2 hr in acetate buffer. Residual activity was
measured as the turnover rate of the DPAP1 specific substrate (Pro-Arg)2-Rho. The kiwas obtained by fitting the data to Equation 1. Standard errors of the fitted
parameters are shown in parentheses.
(D) Ala-4(I)Phe-DMK kills P. falciparum at low nM concentrations. Ring stage parasites were treated with inhibitor and cultured for 75 hr. Parasitemia was
quantified by FACS, and the EC50Pot determined by fitting the data to a dose-response curve.
(E) Phenotypic effects due to Ala-4(I)Phe-DMK treatment. Rings (upper pictures) or schizonts (lower pictures) were cultured for 24 hr in the presence of inhibitor.
Phenotypic effects were visualized in Geimsa-stained thin blood smears.
See also Figure S1.
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DPAP1 Inhibition in P. falciparumwith DPAP3 and the FPs, but that occurs at concentrations that
are 1000-fold higher than those required to inhibit DPAP1 or kill
parasites.
Although the peak of DPAP1 expression occurs at trophozoite
stage, the absolute level of DPAP1 expression remains very high
throughout the erythrocytic cycle (Bozdech et al., 2003; Llinas
et al., 2006), and we have observed DPAP1 activity at all blood810 Chemistry & Biology 17, 808–819, August 27, 2010 ª2010 Elsevistages using FY01 (data not shown). To determine when
DPAP1 activity is most essential, we treated highly synchronous
parasites for 1 hr at different points of the blood stage life cycle
with Ala-4(I)Phe-DMK and monitored parasite growth by FACS
(Figure 2A). This compound kills parasites at all stages of the
life cycle but shows a nearly 10-fold increase in potency against
trophozoite stage parasites.er Ltd All rights reserved
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Figure 2. Stability Requirements for DPAP1 Inhibitors
(A) Trophozoites are more susceptible to DPAP1 inhibition. Parasites at the indicated life stages were treated for 1 hr with Ala-4(I)Phe-DMK. Decrease in
parasitemia was determined by FACS. Error bars show the standard error of three independent measurements.
(B) Structure of SAK2.
(C) Peptidic inhibitors are not stable in mouse serum. The stability of SAK2 and Ala-4(I)Phe-DMK for DPAP1 was determined by measuring their ability to block
labeling of DPAP1 by FY01 either before (top) or after (bottom) overnight incubation in mouse serum.
(D) DPAP1 activity is rapidly restored in living parasites. A culture of mixed-stage parasites was treated with 0.16–100 mM of SAK2 or 0.8–2500 nM of Ala-4(I)
Phe-DMK for 0.5–7 hr. After cell lysis, DPAP1 activity was measured using the DPAP1 specific substrate (Pro-Arg)2-Rho. Representative data are shown in
the upper graph. The IC50DPAP1 values for SAK2 and Ala-4(I)Phe-DMK at each treatment time are shown in the bar graph. The first two bars indicate the EC50Pot
for each compound measured in the standard 75 hr replication assay. Error bars represent the standard deviation of the fitted parameter.
See also Figure S2.
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DPAP1 Inhibition in P. falciparumPeptidic Inhibitors of DPAP1 Are Not Stable
in Mouse Serum
Although Ala-4(I)Phe-DMK is a highly DPAP1 selective inhibitor,
it is not likely to be useful in vivo because it has very poor phar-
macokinetic (PK) properties. Similarly, the poor PK properties of
JCP410, a peptidic inhibitor discovered in our lab (Arastu-Kapur
et al., 2008), explains why it has no effect in vivo (Figure S2). To
determine the stability of peptidic inhibitors, we measured the
ability of Ala-4(I)Phe-DMK and the peptide vinyl sulfone SAK2
(Figure 2B) to inhibit DPAP1 after overnight incubation at 37C
in mouse serum. Both inhibitors lost virtually all of their activity
after pre-incubation in mouse serum (Figure 2C).
SAK2 and Ala-4(I)Phe-DMK inhibit DPAP1 in parasite lysates
at low nanmolar concentrations (Figure 2C), however only
Ala-4(I)Phe-DMK is a potent inhibitor of parasite growth (Fig-
ure 1). SAK2 is 1000-fold less active against parasites in culture
(Figure 2D). To further understand the discrepancy between the
poor efficacy of SAK2 and the high potency of Ala-4(I)-Phe-DMK
against live parasites, we measured DPAP1 activity using our
fluorogenic assay at various time points after treatment with
a range of SAK2 and Ala-4(I)Phe-DMK concentrationsChemistry & Biology 17, 80(Figure 2D). These results indicated that, at >0.8 mM SAK2,
most DPAP1 activity was inhibited within the first 30 min of treat-
ment. However, over the next 7 hr, DPAP1 activity recovered
substantially. This recovery of activity is consistent with the
lack of stability of SAK2 inside parasites, but, because it is a
covalent inhibitor, it also indicates that DPAP1 levels are
replenished by expression or activation of new enzyme.
However, this recovery of activity is not observed with Ala-4(I)
Phe-DMK, which indicates that although unstable in mouse
serum, this inhibitor is stable inside parasites.
Because of the restoration of DPAP1 activity after SAK2 treat-
ment, the IC50DPAP1 increases up to a plateau of 45 mM at 3 hr,
which corresponds to the EC50Pot for SAK2. This suggests that
DPAP1 activity needs to be inhibited for at least 3 hr in order to kill
P. falciparum. Similar dynamics are observed for Ala-4(I)Phe-DMK
where the IC50DPAP1, 2 hr is very similar to the EC50Pot (Figure 1).
In Silico Design of Potent Nonpeptidic Inhibitors
of DPAP1
To overcome the stability issues of peptidic inhibitors, we
screened several recently reported nonpeptidic scaffolds from8–819, August 27, 2010 ª2010 Elsevier Ltd All rights reserved 811
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DPAP1 Inhibition in P. falciparuma large library of compounds that was initially designed to target
cysteine cathepsins in mammals (Brak et al., 2008, 2010; Inagaki
et al., 2007; Patterson et al., 2006; Wood et al., 2005). These
inhibitors use a 2,3,5,6-tetrafluorophenoxyarylmethyl ketone
(TFPAMK) reactive group, and the P1 and P2 residues are linked
through a triazole ring (see Table 1 for structures). We tested only
the molecules in the library containing an N-terminal free amine
(first seven compounds in Table 1) since this is one of the major
determinants of substrate specificity for DPAPs. HN3019 was
the most potent inhibitor against DPAP1 (Table 1). We then
tested whether an acyloxymethylketone (AOMK) or a nitrile
(ML4091 or ML4101, respectively) reactive group would provide
any benefits over the TFPAMK reactive group of HN3019. We
found that the TFPAMK group is 18- and 380-fold more potent
than the AOMK or the nitrile group, respectively. Therefore, the
TFPAMK was chosen for the synthesis of further nonpeptidic
inhibitors.
To guide the synthesis of new compounds, we built
a homology model of DPAP1 based on the crystal structure of
hCat C covalently bound to the Gly-Phe-diazomethane inhibitor
(PDB 2DJF) (Molgaard et al., 2007) (see Figure S3 for the valida-
tion of this model). HN3019 was covalently linked to DPAP1 as
the final product of the reaction between the catalytic cysteine
and the inhibitor (Figure 3A). These models suggested that there
was space on the back side of the S2 pocket that is not filled by
the P2 cyclohexane ring of HN3019. In order to better fill the S2
pocket, we tried opening the cyclohexane ring (compounds
ML4161, ML4123, ML4124, and ML4118S) or adding bulk at
the distal carbon of the cyclohexane ring (compounds
ML4162, ML4163, and ML4154). The latter strategy failed
(Table 1) probably due to steric clashes of the piperidine group
with S2 pocket residues (Figure S3). On the other hand, the
former strategy resulted in compounds with improved potency
toward DPAP1 (Table 1).
ML4118 was initially synthesized as a mixture of the R and S
diastereomers. Based on the docked structures of these two
compounds (Figure 3B), ML4118S would be expected to be
much more potent because its cyclopentane moiety is buried
deep in the S2 pocket while the R isomer leaves this group
partially exposed to the solvent. To test this hypothesis, we
synthesized ML4118S and ML4118R (Figure 4A). We measured
the specificity of these isomers as well as the original racemate
toward different P. falciparum cysteine proteases. As expected,
ML4118S was substantially more potent than ML4118R, while
ML4118 showed intermediate potency (Figures 4B and 4C).
Interestingly, unlike Ala-4(I)-Phe-DMK, ML4118Swas also active
against DPAP3 and FP2/3 (although with reduced potency
compared with DPAP1), indicating that it is a more broad spec-
trum inhibitor (Figures 4B and 4E). In order to correlate target
inhibition with potency against the parasite, we performed inhibi-
tion studies with the ML4118 analogs in intact parasites. These
compounds are cell permeable as they show the same pattern
of DPAP1 inhibition in intact parasites or in lysates (Figure 4C).
Additionally, the same trend in potency observed in the compe-
tition studies in lysates was observed in the replication assay
(Figure 4D). To further correlate parasite death with DPAP1 inhi-
bition, we compared the IC50 values against DPAP1, DPAP3,
and FP2/3 with potency in a 1 hr replication assay since the
IC50 were obtained after 0.5 hr incubation of parasite lysates812 Chemistry & Biology 17, 808–819, August 27, 2010 ª2010 Elseviwith compound prior to probe labeling for 1 hr (Figure 4E). For
both ML4118 and ML4118S, we observed a direct correlation
between specificity and parasite death, with only the IC50 values
for DPAP1 inhibition matching the EC50Pot, 1 hr values in the
replication assay. Because ML4118R is much less potent
against DPAP1, its EC50Pot, 1 hr may reflect some off-target
effects since this compound is also toxic to human foreskin fibro-
blast (HFF) cells at high concentrations (Figure 4E). Importantly,
the fact that ML4118S is more than 500 times more potent than
ML4118R at killing parasites, yet both have similar general
toxicity profiles in HFF cells (EC50Tox 10 mM) suggests that
potency in parasite killing is due to target inhibition rather than
nonspecific toxic effects.
To determine if switching to a nonpeptidic scaffold results in
increased overall stability, we measured the potency of
ML4118S toward DPAP1 before and after overnight incubation
in mouse serum at 37C (Figure 5A). Unlike the peptide inhibitors
(Figure 2C), ML4118S shows only minimal loss of potency after
serum treatment. This increased stability also allowed
ML4118S to induce sustained DPAP1 inhibition in intact para-
sites (Figure 5B). Interestingly, the kinetic inhibition studies in
intact parasites suggest that 1 nM of ML4118S is sufficient to
induce a prolonged inhibition of 70% of DPAP1 activity without
killing parasites (i.e., virtually no effect at 1 nM on overall parasite
replication; Figure 4D). These results, combined with our results
using SAK2, indicate that efficient parasite killing requires at
least 95% inhibition of DPAP1 activity for 2 hr.
Evaluation of the Antiparasitic Activity of ML4118S
in a Mouse Model of Malaria
Because ML4118S is a potent cell permeable DPAP1 inhibitor
that is stable in mouse serum and has overall low toxicity in
HFF cells, we decided to test its in vivo efficacy using a Plasmo-
dium berghei mouse model of malaria. Before testing ML4118S
in vivo, we wanted to make sure that this compound also targets
the DPAP1 homolog in P. berghei (PbDPAP1). We measured
ML4118S specificity toward PbDPAP1 and the FPs homologs,
berghepains 1 and 2 (BP1 and BP2), in P. berghei lysates
(Figure 6A). ML4118S shows inhibition of PbDPAP1 starting at
20 nM with no inhibition of BP2 at concentrations as high as
20 mM. It also has only weak activity toward BP1 at concentra-
tions above 1 mM. Thus, ML4118S is a potent and selective
PbDPAP1 inhibitor in P. berghei.
We initially planned to treat mice infectedwith NK65P. berghei
parasites with 20 mg/kg of ML4118S twice a day for a period of
10 days. We chose this time course for treatment based on the
amount of time it takes for P. berghei parasites to start growing
exponentially in vivo (Figure 6C). In our studies, we found that
parasite levels increase from day 1 to 3 and then temporarily
drop from day 3 to 6. While we cannot explain the reason for
this behavior, we found that it was consistent among all animals
in the trial and therefore does not effect our conclusions
regarding effects of inhibitor treatment. Five mice were treated
with a single dose of ML4118S on the day of infection followed
by two doses (8 hr apart) the next day. Clear signs of compound
toxicity were observed in two mice that were therefore eutha-
nized. On day 2, we decreased the dosage to a single and final
treatment. A third mouse had to be euthanized by day 5 due to
compound toxicity issues. Although we had to discontinueer Ltd All rights reserved
Table 1. Specificity, Potency, and Toxicity Parameters of Nonpeptidic Inhibitors of DPAP1
Compound Name Structure ki (M
-1s-1) IC50DPAP1 (nM) EC50Pot (nM) EC50Tox (nM)
ML4057
H2N
H 520 (30) 700 (40) 3000 (1300) 6500 (1500)
ML4066
H2N
310 (30) 1100 (100) 1000 (500) 8000 (3000)
ML4046A 500 (20) 700 (40) 60 (30) 2100 (300)
ML4046B <20 >20,000 3800 (3000) 10,500 (500)
ML4053
H2N
1.6 (0.2) >100,000 35,000 (30,000) 8300 (400)
ML4068
H2N
H
4.9 (0.5) 74,000 (9000) 3000 (2000) >100,000
HN3019
H2N
630 (30) 560 (40) 70 (30) >100,000
ML4161
H2N
810 (50) 410 (30) 35,000 (30,000) 90,000 (20,000)
ML4123
H2N
910 (50) 410 (10) 20 (10) 5500 (2500)
ML4124
H2N
510 (40) 700 (50) 140 (60) >100,000
ML4118
H2N
2070 (30) 186 (2)a 19 (2) 9300 (600)
ML4118S
H2N
16,500 (1200) 19 (1) 5.2 (0.5) 8500 (1500)
ML4118R
H2N
28 (3) 14,000 (1500)a 890 (520) 7000 (2000)
ML4162
H2N
HN <20 >20,000 220 (160) 68,000 (4000)
ML4163
H2N
N
O <20 >20,000 >100,000 >100,000
ML4154
H2N
NH2N
O <20 >20,000 45,000 (26,000) 30,000 (5000)
ML5004
NH
50 (2) 7700 (200)a n.d. n.d.
ML6076
NH
920 (70) 420 (30) 930 (130) n.d.
ML4091
N
NN
O
O
H2N O
34 (2) 11,000 (1000) 6000 (3000) 12,000 (3000)
ML4101
N
NN
H2N
N 1.7 (0.2) >100,000 >100,000 >100,000
DPAP1 inhibition was measured using our DPAP1-specific fluorogenic assay. IC50DPAP1 were determined after 30 min incubation of parasite lysates
with 5 nM to 100 mM inhibitor. ki values were obtained by fitting the data to Equation 1. EC50Pot values were measured using our standard 75 hr
replication assay. Cell toxicity (EC50Tox) was determined by measuring ATP production after 24 hr treatment of HFF cells with 0.01–100 mM of
compound. All IC50 and EC50 were obtained by fitting the data to a dose-response curve.
n.d., not determined.
a IC50DPAP1 and ki values were obtained using the competition assay between inhibitor and probe rather than the fluorogenic assay. The standard
errors of the fitted parameters are shown in parentheses.
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ML4118S
ML4118R
B
S2 Pocket
A
Catalytic
Cysteine
Figure 3. In Silico Design of Nonpeptidic Inhibitors for DPAP1
(A) Docking of HN3019 and ML4118S into the active site of the DPAP1 model.
HN3019 (green) and ML4118S (cyan) were docked as the final covalent
product of the reaction between the inhibitor and the catalytic cysteine. The
structure of the DPAP1 model bound to HN3019 is shown as an electrostatic
surface.
(B) Docking of ML4118S (cyan) and ML4118R (orange) into the active site of
the DPAP1 model.
See also Figure S3.
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DPAP1 Inhibition in P. falciparumdosing due to toxicity of the compound, we collected blood from
days 2 through 15 for the surviving animals and estimated the
percentage parasitemia by Geimsa-stained thin blood smear
or FACS (Figure 6C). Due to the toxicity of the compound, we
were unable to repeat the studies with a larger group of animals,814 Chemistry & Biology 17, 808–819, August 27, 2010 ª2010 Elsevithus the in vivo data must be interpreted with caution. Regard-
less, we observed a significant decrease in parasitemia on the
days following treatment with ML4118S (days 2–4) (inset
Figure 6C).
Because the toxicity of ML4118S limited the utility of the
compound, we decided to shift our efforts to a related
compound (KB16) known to have low toxicity in mice (no toxicity
at 20 mg/kg/day for 3 weeks). KB16 was designed to target the
cysteine protease cruzain from Trypanosoma cruzi (Brak et al.,
2008) and has a reasonably long half-life in blood (3–4 hr).
Unfortunately, KB16 is not a very potent inhibitor of PbDPAP1
(IC50DPAP1 1 mM) (Figure 6B). However, because it is an irre-
versible inhibitor with a long half-life in blood, we thought it might
have a chance to sustain PbDPAP1 inhibition in vivo. When
infected mice were treated from day 0 to 9 with 20 mg/kg/day
of KB16, we observed a significant decrease of parasitemia up
to day 14 (Figure 6C). Given that KB16 also targets BP1
(IC50BP1 0.5 mM), it is possible that the decrease in parasitemia
is due to a combined effect of BP1 and DPAP1 inhibition. Taken
together, our in vivo results suggest that inhibition of DPAP1may
be a viable means to reduce parasite growth in vivo.
DISCUSSION
The hemoglobin degradation pathway has been pursued as a
potential site for intervention with antimalarial drugs for the last
20 years (Francis et al., 1997). However, most of the efforts to
block this essential pathway have focused on inhibition of the
FPs (Rosenthal et al., 2002) and plasmepsins (Ersmark et al.,
2006) in the FV. All of these proteases are important for the initial
stages of hemoglobin degradation but their biological roles in
this pathway have been shown to be redundant not only within
a protease family but also between families (Bonilla et al.,
2007a, 2007b). Single andmultiple genetic knockouts of FV plas-
mepsins (Liu et al., 2005; Omara-Opyene et al., 2004), and dele-
tion of FPs 1 and 2 are not lethal (Sijwali et al., 2006). On the other
hand, there is only one DPAP in this pathway, and efforts to
knock out this enzyme suggest that it is essential (Klemba
et al., 2004). Therefore, DPAP1 is likely to be a more suitable
target for drug development than the FV FPs or plasmepsins.
In this study, we show that selective inhibition of DPAP1 by
Ala-4(I)Phe-DMK results in parasite death in culture. This inhib-
itor has at least 1000-fold selectivity toward DPAP1 over the
other papain fold cysteine proteases of P. falciparum (DPAP3
and the FPs). Several lines of evidence suggest that Ala-4(I)
Phe-DMK effects on parasites are specifically due to inhibition
of DPAP1 rather than the result of off-target effects. First,
DPAP1 inhibition closely correlates with parasite death
(IC50DPAP1, 2 hr = 2.0 nM; EC50Pot = 2.8 nM). Second, parasites
are ten times more sensitive to Ala-4(I)Phe-DMK at the tropho-
zoite stage consistent with the role of DPAP1 in hemoglobin
degradation, a pathway that is most essential at trophozoite
stage. Third, the phenotypic effect observed for this inhibitor
(i.e., formation of an underdeveloped trophozoite), is in agree-
ment with DPAP1 being the primary target since the same
phenotype was observed in parasite treated with SAK2, P-hF-
AOMK, and A-4(I)F-AOMK, which are selective covalent
DPAP1 inhibitors whose reactive groups are structurally unre-
lated to Ala-4(I)Phe-DMK (Figure S1). Finally, the correlationer Ltd All rights reserved
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(A) Structures. ML4118 is a mixture of the R and S
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(B) Specificity toward DPAPs and flacipains (FPs)
measured using the competition assay.
(C) DPAP1 Inhibition in intact parasites versus
lysates. Purified schizonts (filled symbols) or
lysates (empty symbols) were treated with
ML4118S (triangles), ML4118 (diamonds), or
ML4118R (circles) followed by labeling with FY01
for 1 hr.
(D) Potency of killing parasites determined using
a 75 hr replication assay.
(E) Specificity versus potency versus toxicity. IC50
values were obtained by quantifying the gel bands
shown in (B). EC50Pot values were determined by
FACS after treating schizonts for 1 hr with
compound, followed by three washes with media,
and culture of the parasites for another 48 hr. Cell
toxicity was determined by incubating HFF cells
for 24 hr with inhibitor and measuring ATP produc-
tion using the CellTiter-Glo assay.
Error bars represent the standard deviation of the
fitted parameter.
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DPAP1 Inhibition in P. falciparumbetween DPAP1 inhibition and potency in the replication
assay was also observed for our library of nonpeptidic inhibitors.
The ki and EC50Pot values of Table 1 show that the stronger an
inhibitor is against DPAP1, the more potent it is at killing para-
sites. More specifically, the dramatic difference in potency
between the ML4118S and ML4118R diastereomers indicatesChemistry & Biology 17, 808–819, August 27, 2010that these compounds are not killing
parasites by nonspecific toxic effects.
Although the original peptidic vinylsul-
fone inhibitors were not suitable for use
in vivo due to their overall lack of stability,
they allowed us to study the dynamics of
DPAP1 expression/activation in living
parasites (Figure 2). Studies of DPAP1
inhibition over time showed that DPAP1
activity recovers rapidly after it has been
irreversibly inhibited. This implies that
either DPAP1 is constantly expressed
and trafficked into the FV to replenish the
DPAP1 activity that is lost due to protease
turnover, or thatP. falciparum tightly regu-
lates the levels of DPAP1 activity and is
able to respond to a drop in activity.
We also provide several lines of
evidence to show that sustained inhibi-
tion of DPAP1 for 2–3 hr is required to
prevent the recovery of activity and
induce parasite death. The potency of
Ala-4(I)Phe-DMK in the parasite replica-
tion assay corresponds to the IC50DPAP1
after 2 hr of treatment of parasite lysates
(Figure 1). Furthermore, the IC50DPAP1
for SAK2 reaches a plateau after 3 hr of
treatment that corresponds to its EC50Pot
in the replication assay (Figure 2). Therefore, an effective drug
against DPAP1 either needs to have a long half-life in blood or
be designed such that it will be retained inside the FV for several
hours. In theory, this could be achieved by taking advantage of
the acidic environment inside the FV or by using a prodrug
strategy to enhance stability in blood.ª2010 Elsevier Ltd All rights reserved 815
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Serum and Sustains DPAP1 Inhibition
(A) Serum stability of ML4118S. The stability was
determined by measuring their ability of the
ML41118S to block labeling of DPAP1 by FY01
either before (top) or after (bottom) overnight incu-
bation in mouse serum.
(B) Kinetics of DPAP1 inhibition by ML4118S in
intact parasites. DPAP1 activity in a mix-stage
parasite culture was measured after treatment
with ML4118S over a range of times. DPAP1
activity was measured using the DPAP1-specific
substrate (Pro-Arg)2-Rho.
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DPAP1 Inhibition in P. falciparumWe were able to overcome the stability problems of peptidic
DPAP1 inhibitors by switching to a nonpeptidic scaffold. More-
over, homology modeling and computational docking methods
allowed us to improve the specificity of our initial hit, HN3019,
by more than 25-fold. This suggests that in silico methods may
be valuable for the design of DPAP inhibitors. Analysis of the
structure activity relationship (SAR) of our two classes of
compounds, dipeptide vinylsulfone (Table S1) and nonpeptidic
TFPAMK (Table 1) inhibitors indicates that short amino acid
side chains are preferred at the S2 pocket (see Supplemental
Material for a detailed SAR analysis). For peptidic inhibitors,
Pro in P2 or 4(I)Phe in P1 enhances inhibitor selectivity toward
DPAP1 with respect to the other papain fold cysteine proteases
(Figure S1). Interestingly, a Pro in P2 within the context of the
nonpeptidic scaffold (ML6076) does not result in a DPAP1 selec-
tive inhibitor (Figure S1). Finally, our results with KB16 suggest
that secondary amines in P2 might improve the PK and toxicity
properties of nonpeptidic inhibitors.
In this study, we also showed that DPAP1 inhibitors have
effects on parasite growth in vivo. In P. berghei, ML4118S is
a much more specific inhibitor of DPAP1 than in P. falciparum.
Although this inhibitor has toxicity issues in mice at 20 mg/kg,
we were able to observe a significant decrease in parasitemia
2 days after treatment. Unfortunately, the relatively small sample
size that was caused by compound toxicity, coupled with overall
animal-to-animal variability in parasite growth makes our data
with ML4118S still less than conclusive. However, we did find
that the nontoxic KB16 resulted in a significant decrease in
parasitemia during the 10 days of treatment. Although these
results suggest that DPAP1 inhibition can lead to a decrease in
parasitemia in vivo, additional studies using less toxic and
more selective inhibitors will be required to confirm our findings.
We are currently working toward the development of selective,
nontoxic DPAP1-specific compounds that have long half-lives
in blood. These compounds should allow us to confirm that
DPAP1 inhibition can clear parasitemia in vivo.
In general the papain-fold proteases are likely to be interesting
as potential antimalarial drug targets. Members of this family of
proteases play essential roles in various aspects of Plasmodium
biology, and inhibitors that target multiple family members may
be beneficial over compounds that target only one member.
Furthermore, the fact that the closest related human homolog816 Chemistry & Biology 17, 808–819, August 27, 2010 ª2010 Elsevito DPAPs can be inhibited without any significant toxic effects
suggests that parasite specific targeting may not need to be a
priority in drug design for this target family.While the compounds
described in this study are certainly not optimal as drug leads
due to lack of potency, poor PK and/or toxicity issues, they do
provide the first direct evidence that DPAP1 is a viable antima-
larial drug target. Based on these promising results, we have
recently completed a screen of more than 100,000 small mole-
cules using a DPAP1 specific fluorogenic substrate assay in
parasite lysates. This screen has identified many new inhibitor
scaffolds that we are currently evaluating for their viability as
potential drug leads.
SIGNIFICANCE
The emergence of drug resistance in malaria species
continues to be the main hurdle to treat this devastating
disease. In order to control this pandemic disease, it is
crucial to identify new drug targets that can expand the port-
folio of antimalaria drugs. This work demonstrates the
potential of targeting DPAP1 with small molecules. We
showed that DPAP1 inhibition impairs parasite develop-
ment, thus validating this cysteine protease as a new anti-
malarial target. Additionally, we showed that in silico
methods can be successfully applied to design potent
DPAP inhibitors. Finally, we demonstrated that the nonpep-
tidic inhibitors presented in this work have improved
stability compared to more classical, peptidic-based,
protease inhibitors. Overall, our results validate DPAP1 as
an antimalarial target but also indicate that effective DPAP
drugswill require either long half-lives or high retention in in-
fected RBCs to sustain DPAP1 inhibition for several hours.
EXPERIMENTAL PROCEDURES
Protease Inhibitor Synthesis and Characterization
Ala-4(I)Phe-DMK was a valuable gift from David Percival (Merck); its synthesis
and characterization was described in (Guay et al., 2009). The vinyl sulfone
inhibitors used in this study were described in Arastu-Kapur et al. (2008),
and KB16 was characterized in Brak et al. (2008). The AOMK inhibitors were
synthesized as described in Kato et al. (2005). The synthesis and characteriza-
tion of all other nonpeptidic inhibitors are described in the Supplemental
Experimental Procedures.er Ltd All rights reserved
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Figure 6. Nonpeptidic DPAP1 Inhibitors
Decrease Parasite Load In Vivo
(A and B) Specificity of ML4118S (A) and KB16 (B)
for PbDPAP1, BP1, and BP2 using competition
assays in P. berghei lysates.
(C) Parasite growth in mice after treatment with
ML4118S and KB16. Treatment with 20 mg/kg
of compound via IP is indicated with black
(KB16, n = 4) or gray (ML4118S, n = 2–5) dots. Par-
asitemia was quantified by Geimsa-stained thin
blood smears (days 2–6) or by FACS (days 7–15).
Control mice were treated either following the
ML4118S (n = 2) or the KB16 (n = 3) treatment
schedule. No difference in parasitemia was
observed between the two sets of control mice.
The value reported for the vehicle-treated mice is
the average of the five control mice. Asterisks indi-
cate significant differences between vehicle and
drug-treated mice (p-values were determined
using the Student’s t test: *p > 0.95; **p > 0.99;
***p > 0.999).
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DPAP1 Inhibition in P. falciparumParasite Culture, Harvesting, and Lysate Preparation
3D7 and D10 P. falciparum clones were cultured as described in (Arastu-Kapur
et al., 2008). To tightly synchronize D10 parasiteswithin a 1 hr window, schizonts
wereharvested6hrprior to rupture usinga70%percol gradientandcultureduntil
they were rupturing. Blood was then added to this culture, and merozoites were
allowed to invadeuninfectedRBCs for 1hr.Newly formed ringswerepurifiedwith
a sorbitol treatment. 3D7 parasites were grown asynchronously and were used
when a mixed-stage parasite culture was needed. Parasite pellets and lysates
were obtained as described in (Arastu-Kapur et al., 2008).
Labeling of Cysteine Protease Activity with ABPs and Competition
of Labeling by Protease Inhibitors
FY01, a cell permeable fluorescently tagged probe, and radiolabeled
125I-DCG04 were used to label the activity of DPAPs and FPs, respectively,
in intact schizonts or parasite lysates (in acetate buffer: 50mMsodium acetate,
5 mMMgCl2, and 5 mM DTT [pH 5.5]). Labeling and competition assays were
performed as described in (Arastu-Kapur et al., 2008).
ki Determination Using a Fluorogenic Activity Assay for DPAP1
(Pro-Arg)2-Rho is a DPAP1 specific substrate in parasite lysates (Deu et al.,
2010). DPAP1 activity was measured at 25C in acetate buffer containingChemistry & Biology 17, 808–819, August 27, 20101% of parasite lysates and 10 mM (Pro-Arg)2-
Rho. Substrate turnover was measured for 5 min
in a 96-well plate at 523 nm (lexcitation =
492 nm and an emission cutoff filter at 515 nm)
in a Spectramax M5 plate-reader (Molecular
Devices).
Accurate ki values (second order rate constant
of inhibition) were obtained by treating parasite
lysates in acetate buffer with inhibitor for a given
period of time (t). Residual DPAP1 activity was
measured using our fluorogenic assay. The rates
of substrate turnover relative to DMSO controls
(v/v0) were fitted to a simple irreversible inhibitor
model E+ I/
ki
E I (Eq. 1).
v=v0 = expð  ki$½I$tÞ (1)
Kinetics of DPAP1 Inhibition and Activation
in Intact Parasites
A mix-stage culture of 3D7 parasites at 20%
parasitemia was treated with different concentra-tions of inhibitor or DMSO. Two hundred microliter aliquots of culture were
taken after 0.5–7 hr of treatment, and the RBCs were lysed in 100 ml of acetate
buffer by three cycles of freezing in liquid nitrogen and thawing at 37C. DPAP1
activity was measured using the fluorogenic assay.
P. falciparum Replication Assay
Two hundred microliters of synchronous D10 parasites at ring stage (2%
parasitemia and 0.5% hematocrit) were treated with compound and cultured
in 96-well plates for 75 hr, when the DMSO controls reach schizont stage.
Infected and uninfected RBCs were quantified by FACS as described
in Arastu-Kapur et al. (2008). All FACS measurements were taken on a BD
FACScan flow cytometer (Becton Dickinson). All EC50Pot values for parasite
death were obtained by fitting the parasitemia values to a dose-response
curve.
Susceptibility of the Different Life Cycle Stages to DPAP1 Inhibition
Tightly synchronized parasites were treated for 1 hr with Ala-4(I)Phe-DMK or
DMSO at early rings (1 hr postinvasion [p.i.]), rings (10 hr p.i.), late rings
(18 hr p.i.), trophozoites (30 hr p.i.), schizonts (38 hr p.i.), or late schizonts
(46 hr p.i.). Cells were then washed three times with media and cultured until
the DMSO control parasites progressed through egress, and newly infectedª2010 Elsevier Ltd All rights reserved 817
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DPAP1 Inhibition in P. falciparumRBCs reached schizont stage (80 hr p.i.). Parasitemia was quantified by
FACS.
Cell Toxicity
Two hundred microliters of an HFF culture was incubated in a 96-well plate
for 24 hr with inhibitor or DMSO. Cell viability was measured using the
CellTiter-Glo Assay (Promega) according the manufacturer’s instructions.
EC50Tox values were obtained by fitting the data to a dose-response curve.
Homology Modeling and Docking
The homology model of DPAP1 was built based on the crystal structure of
hCatC covalently bound to the Gly-Phe-diazomethane inhibitor (PDB 2DJF)
(Molgaard et al., 2007) using the default parameters of theMolecular Operating
Environment (MOE) software (Chemical Computing group). To dockHN3019 in
the homologymodel of DPAP1, the inhibitor backbone was oriented according
to the structure of human cathepsin S bound to a nonpeptidic chloro-methyl
ketone inhibitor (PDB 2H7J) (Patterson et al., 2006) that has the same inhibitor
backbone as HN3019. We decided to dock the structure of HN3019 as the
product of the reaction between the warhead and the active site, i.e., the
catalytic cysteine was covalently linked to the a-carbon of the inhibitor after
displacement of the tetrafluorophenoxy group.
Energy minimizations of the P2, P1, and covalently modified cysteine were
performed sequentially followed by an energy minimization of the full molecule
and the catalytic cysteine side chain. A final energy minimization including
HN3019 and all side chains within 4.5 A˚ yielded our final model of DPAP1
bound to HN3019. All energy minimizations were performed using the default
parameters in MOE. To dock other nonpeptidic inhibitors, the P2 position of
HN3019 bound to the DPAP1model was modified to that of the new inhibitors,
and the structure of the inhibitor-protein complex was energy minimized as
described above.
Infection of Mice with P. berghei Parasites and Treatment
with DPAP1 Inhibitors
All mouse experiments were approved by the Stanford Administration Panel
on Laboratory Animal Care and strictly followed their specific guidelines.
Balb/c female mice (20–24 g) were infected via tail vein (day 0) with 1 million
of freshly collected parasites from an infected mouse. All treatments were
administered via IP in 45% polyethylene glycol (M.W. 400), 35% propylene
glycol, 10% ethanol, 10% DMSO, and 10% w/v 2-hydroxypropyl b-cyclodex-
trin. Mice treated with ML4118S (n = 5) were administered a dose of 20 mg/kg
in 200 ml of vehicle on day 0, two on day 1, and a last one on day 2. KB16 treat-
ment was administered once a day from day 0 to 9 at 20 mg/kg (n = 4). Control
micewere treatedwith vehicle following either theML4118S (n = 2) or the KB16
(n = 3) treatment schedules. Blood was collected from the tail and analyzed by
FACS and Geimsa-stained thin blood smears from days 2 to 15. Mice were
euthanized on day 15.
Determination of Parasitemia in Mouse Blood
ParasitemiawasquantifiedbyFACSwhen it reachedmore than2% (days6–15).
Fromdays 2 to 5, the parasite loadwas too low to get accurate quantification by
FACS, and parasitemiawas quantified fromGeimsa-stained thin blood smears.
Parasitemiawas estimated by counting all infected RBCs in 15–20 optical fields
containing 200–1000 cells. For each field the total number of RBCswas roughly
estimated. The final parasitemia for each mouse and day was determined from
an estimate of more than 10,000 RBCs per slide.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at
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